About the Authors
- Jörg Tomeczkowski
-
* E-mail: jtomeczk@its.jnj.com
Affiliation Department of Health Economics, Janssen-Cilag GmbH, Neuss, Germany
- Sean Stern
-
Affiliation United Biosource Corporation, Bethesda, Maryland, United States of America
- Alfred Müller
-
Affiliation Analytic Services GmbH, München, Germany
- Christian von Heymann
-
Affiliation Department of Anesthesiology and Intensive Care Medicine, Charité-University Medicine Berlin, Campus Virchow-Klinikum, Berlin, Germany
Competing Interests
JT is an employee of Janssen-Cilag GmbH (Johnson & Johnson). Janssen-Cilag holds the marketing authorization for ERYPO®/EPREX®/PROCRIT® (Epoetin alfa) used in this model. SS is an employee of United Biosource Corporation and received an honorarium for the model validation and for working on the manuscript. AM received an honorarium for the programming of the model. CvH has received honoraria for consultancy work and lectures from Janssen-Cilag GmbH (Johnson & Johnson), Vifor Pharma GmbH, Munich, and the German Red Cross, Hagen, Germany. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JT AM SS CvH. Performed the experiments: JT AM. Analyzed the data: JT AM SS CvH. Contributed reagents/materials/analysis tools: JT AM CvH. Wrote the paper: JT AM SS CvH.